• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.

    5/7/25 9:31:20 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TNYA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Tenaya Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    87990A106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    87990A106


    1Names of Reporting Persons

    Empery Asset Management, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,727,314.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,727,314.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,727,314.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.96 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    87990A106


    1Names of Reporting Persons

    Ryan M. Lane
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,727,314.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,727,314.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,727,314.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.96 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    87990A106


    1Names of Reporting Persons

    Martin D. Hoe
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,727,314.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,727,314.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,727,314.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.96 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Tenaya Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    171 Oyster Point Blvd., Suite 500, South San Francisco, CA 94080
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to Common Stock, par value $0.0001 per share (the "Common Stock") of Tenaya Therapeutics, Inc., a Delaware corporation (the "Company"): (i) Empery Asset Management, LP (the "Investment Manager"), with respect to the Common Stock held by funds to which the Investment Manager serves as investment manager (the "Empery Funds"); (ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the Common Stock held by the Empery Funds; and (iii) Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the Common Stock held by the Empery Funds.
    (b)Address or principal business office or, if none, residence:

    1 Rockefeller Plaza, Suite 1205, New York, New York 10020
    (c)Citizenship:

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    87990A106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 87,582,646 shares of Common Stock outstanding as of March 4, 2025, as reported in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2025. The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all of the Common Stock held by the Empery Funds. Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all of the Common Stock held by the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such Common Stock.
    (b)Percent of class:

    9.96%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a) above.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Empery Asset Management, LP
     
    Signature:/s/ Ryan M. Lane
    Name/Title:By: Empery AM GP, LLC, its General Partner, By: Ryan M. Lane, its Managing Member
    Date:05/07/2025
     
    Ryan M. Lane
     
    Signature:/s/ Ryan M. Lane
    Name/Title:Ryan M. Lane, individually
    Date:05/07/2025
     
    Martin D. Hoe
     
    Signature:/s/ Martin D. Hoe
    Name/Title:Martin D. Hoe, individually
    Date:05/07/2025
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $TNYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNYA

    DatePrice TargetRatingAnalyst
    6/10/2024Outperform
    William Blair
    11/30/2023$7.00Outperform
    Leerink Partners
    6/15/2022$25.00Buy
    H.C. Wainwright
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$31.00Overweight
    Morgan Stanley
    8/24/2021$37.00Buy
    Chardan Capital
    8/24/2021$40.00Overweight
    Piper Sandler
    More analyst ratings

    $TNYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025 Cash Runway Extended into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies tha

      5/7/25 4:05:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

      RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease Progression Despite Standard-of-Care Treatments Large Majority of PKP2-associated ARVC Patients Appear Eligible for TN-401 Gene Therapy Based on Low Rates of Preexisting Immunity to AAV9 Antibodies SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of hea

      4/24/25 2:07:47 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

      TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart

      3/31/25 10:00:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

      Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a

      4/26/23 7:00:00 AM ET
      $NKTX
      $TNYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

      SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. "We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercia

      12/7/22 4:30:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Provides 2022 Business Updates

      Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC) IND applications for TN-201 and TN-301 (previously named TYA-11631) expected to be submitted in the second half of 2022 Appoints Jennifer Drimmer, J.D., as General Counsel Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic

      1/10/22 8:00:00 AM ET
      $EXEL
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Column Group Iii Gp, Lp bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:40 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Goeddel David V bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:15 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Column Group Iii Gp, Lp bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      2/14/24 4:15:53 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Tenaya Therapeutics Inc.

      10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/7/25 4:27:33 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/7/25 4:18:33 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.

      SCHEDULE 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      5/7/25 9:31:20 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Tenaya Therapeutics

      William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform

      6/10/24 7:25:34 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Leerink Partners initiated coverage on Tenaya Therapeutics with a new price target

      Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00

      11/30/23 7:50:26 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Tenaya Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $25.00

      6/15/22 7:41:04 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      11/14/24 5:46:12 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      11/14/24 1:22:39 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      2/14/24 5:01:36 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Financials

    Live finance-specific insights

    See more
    • Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

      TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported encouraging

      12/17/24 7:00:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

      SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register her

      12/16/24 4:30:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TNYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Finance Higa Tomohiro sold $1,336 worth of shares (2,482 units at $0.54), decreasing direct ownership by 2% to 99,690 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:44:50 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Tingley Whittemore sold $3,983 worth of shares (7,398 units at $0.54), decreasing direct ownership by 4% to 174,793 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:43:12 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Ali Faraz sold $5,245 worth of shares (9,741 units at $0.54), decreasing direct ownership by 3% to 320,514 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:42:17 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care